James E. Levine
Chief Financial Officer at Kazia Therapeutics Ltd (KZIA) since June 2026
James E. Levine has filed 11 insider reports with the SEC since March 2021, as chief Financial Officer at Kazia Therapeutics Ltd (KZIA), chief Financial Officer at Cardiff Oncology, Inc. (CRDF) and officer at Cidara Therapeutics, Inc. (CDTX). James E. Levine made no open-market purchases or sales in the last 12 months. The latest filing, on June 23, 2026, reports grant or award at Kazia Therapeutics Ltd (KZIA).
- Filings
- 11
- Companies
- 3
- Bought on market
- $277K
- Sold on market
- None
Companies where James E. Levine is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Financial Officersince June 2026 | $5.49 | Jun 23, 2026 | |||||
| Chief Financial Officersince July 2021 | 60,000 | $277K | $4.10 | $0.839-80% | Mar 13, 2025 | ||
| Officer | 69,803 | Mar 20, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Jun 19, 2026KZIASEC Form 4 filed by Chief Financial Officer Levine James E.Form 4Grant or award
- Jun 1, 2026KZIAJames E. Levine became an insiderForm 3New insider
- Mar 11, 2025CRDFSEC Form 4 filed by Chief Financial Officer Levine James E.Form 4Grant or award
- Dec 18, 2024+$36.7KCRDFChief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76)Form 4Open-market purchase
- Mar 7, 2024CRDFSEC Form 4 filed by Levine James E.Form 4Grant or award
- Mar 15, 2023CRDFSEC Form 4 filed by Levine James E.Form 4Grant or award
- Sep 16, 2022+$46.7KCRDFSEC Form 4: Levine James E. bought $46,710 worth of shares (30,000 units at $1.56), increasing direct ownership by 100% to 60,000 unitsForm 4Open-market purchase
- Mar 9, 2022CRDFSEC Form 4 filed by Levine James E.Form 4Grant or award
- Sep 10, 2021+$194KCRDFSEC Form 4: Levine James E. bought $194,000 worth of Common Stock (30,000 units at $6.47)Form 4Open-market purchase
- Jul 12, 2021CRDFSEC Form 3 filed by Levine James E.Form 3New insider
- Mar 17, 2021CDTXSEC Form 4 filed by E. James LevineForm 4Grant or award
Compare James E. Levine with
- James E. Levine vs Gary W Pace1 shared
- James E. Levine vs Mani Mohindru1 shared
- James E. Levine vs Coffey Steven R. S.1 shared
- James E. Levine vs John E. Friend II1 shared
- James E. Levine vs Jeffrey Bonacorda1 shared
- James E. Levine vs Ebru Davidson1 shared
Other insiders at the same companies
- Gary W PaceCRDF
- Mani MohindruCRDF
- Coffey Steven R. S.KZIA
- John E. Friend IIKZIA
- Jeffrey BonacordaKZIA
- Ebru DavidsonKZIA
- David CainKZIA
- Robert F AppleKZIA
- Sudha RaoKZIA
- Rodney S MarkinCRDF
- Renee P TannenbaumCRDF
- James O ArmitageCRDF
- Lale WhiteCRDF
- Ajay AggarwalCRDF
- Joshua B MuntnerCRDF
- Tod SmealCRDF
Questions about James E. Levine
- What is James E. Levine's role at Kazia Therapeutics Ltd?
- James E. Levine reports to the SEC as chief Financial Officer at Kazia Therapeutics Ltd (KZIA), according to the latest filing on June 23, 2026. James E. Levine has also filed as chief Financial Officer at Cardiff Oncology, Inc. (CRDF) and officer at Cidara Therapeutics, Inc. (CDTX).
- How many shares does James E. Levine own?
- After the latest filing that states it, James E. Levine directly owned 60,000 shares of Cardiff Oncology, Inc. (CRDF) and 69,803 shares of Cidara Therapeutics, Inc. (CDTX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has James E. Levine bought or sold stock recently?
- The most recent open-market purchase was on December 18, 2024: bought 7,716 shares of Cardiff Oncology, Inc. (CRDF) for $36.7K at an average of $4.76.
- How do I get alerts when James E. Levine files?
- Follow James E. Levine on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by James E. Levine (SEC CIK 0001463151). Totals count each trade once, skipping amendments whose original is on file, from Mar 20, 2021 on. View on SEC EDGAR